Abstract
Objective
Describe the clinical manifestations and genetic variants of Noonan syndrome (NS) in a Colombian pediatric population and to identify the genes most frequently associated with specific phenotypic features.
Methods
A retrospective observational study was conducted on patients under 18 years of age diagnosed with NS between 2013 and 2023. Clinical and molecular data were collected from medical records across several hospitals in Colombia. Molecular confirmation was achieved in all included patients through next generation sequencing-based clinical exome sequencing. However, parental samples were not available for segregation analysis in all cases. Descriptive statistical analyses were performed using R version 4.3.1 to evaluate demographic, clinical, and genetic variables.
Results
Among the 45 patients included (21 females, 24 males; mean age at diagnosis 7.5±5.2 years), pathogenic variants were identified across 13 genes, with PTPN11 being the most frequent (26/45, 57.8%), followed by PPP1CB and several less frequent genes including SOS1, SOS2, LZTR1, RAF1, MAP2K1, KRAS, NRAS, BRAF, CBL, NF1, and SHOC2. The most common phenotypic features were congenital heart defects (80%, 36/45), predominantly pulmonary stenosis (31.1%, 14/45), short stature (66.7%, 30/45), and learning difficulties (51.1%, 23/45). Seven patients developed neoplasms. Juvenile myelomonocytic leukemia was the most frequent neoplasm and occurred mainly in patients with PTPN11 variants. Ten patients (22.2%) received growth hormone therapy.
Conclusion
This study represents the first genetically characterized Colombian cohort for NS. PTPN11 was the predominant gene identified, particularly the p.(Asn308Asp) variant. These findings reiterate the genetic heterogeneity of NS in Colombian children and the importance of early molecular diagnosis to guide clinical management. Multidisciplinary follow-up is essential due to the risks of growth failure, cardiac anomalies, and malignancies.
Keywords: Noonan syndrome, PTPN11, RASopathy
Read the full text
5 sections · 1 figure · 3 tables · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Edouard T, Cartault A. Gonadal function in Noonan syndrome. Ann Endocrinol (Paris). 2022;83:203-206. Epub 2022 Apr 27
Rodríguez F, Gaete X, Cassorla F. Etiology and treatment of growth delay in Noonan syndrome. Front Endocrinol (Lausanne). 2021;12:691240.
Linglart L, Gelb BD. Congenital heart defects in Noonan syndrome: diagnosis, management, and treatment. Am J Med Genet C Semin Med Genet. 2020;184:73-80. Epub 2020 Feb 5
Christou EE, Zafeiropoulos P, Rallis D, Baltogianni M, Asproudis C, Stefaniotou M, Giapros V, Asproudis I. A narrative review of the ocular manifestations in Noonan syndrome. Semin Ophthalmol. 2022;37:215-221. Epub 2021 Jul 19
Marcinowski F. Oskar Kobyliński (1856-1926) and the first description of Noonan syndrome in the medical literature. J Med Biogr. 2020;28:202-207. Epub 2018 Jul 12
Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. The Lancet. 2013;381:333-342. Epub 2013 Jan 10
Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126:746-759. Epub 2010 Sep 27
Tajan M, Paccoud R, Branka S, Edouard T, Yart A. The RASopathy family: consequences of germline activation of the RAS/MAPK pathway. Endocr Rev. 2018;39:676-700.
Baban A, Olivini N, Lepri FR, Calì F, Mucciolo M, Digilio MC, Calcagni G, di Mambro C, Dallapiccola B, Adorisio R, Novelli A, Drago F. SOS1 mutations in Noonan syndrome: Cardiomyopathies and not only congenital heart defects! Report of six patients including two novel variants and literature review. Am J Med Genet A. 2019;179:2083-2090. Epub 2019 Aug 1
Baldo F, Fachin A, Da Re B, Rubinato E, Bobbo M, Barbi E. New insights on Noonan syndrome’s clinical phenotype: a single center retrospective study. BMC Pediatr. 2022;22:734.
Kruszka P, Porras AR, Addissie YA, Moresco A, Medrano S, Mok GTK, Leung GKC, Tekendo-Ngongang C, Uwineza A, Thong MK, Muthukumarasamy P, Honey E, Ekure EN, Sokunbi OJ, Kalu N, Jones KL, Kaplan JD, Abdul-Rahman OA, Vincent LM, Love A, Belhassan K, Ouldim K, El Bouchikhi I, Shukla A, Girisha KM, Patil SJ, Sirisena ND, Dissanayake VHW, Paththinige CS, Mishra R, Klein-Zighelboim E, Gallardo Jugo BE, Chávez Pastor M, Abarca-Barriga HH, Skinner SA, Prijoles EJ, Badoe E, Gill AD, Shotelersuk V, Smpokou P, Kisling MS, Ferreira CR, Mutesa L, Megarbane A, Kline AD, Kimball A, Okello E, Lwabi P, Aliku T, Tenywa E, Boonchooduang N, Tanpaiboon P, Richieri-Costa A, Wonkam A, Chung BHY, Stevenson RE, Summar M, Mandal K, Phadke SR, Obregon MG, Linguraru MG, Muenke M. Noonan syndrome in diverse populations. Am J Med Genet A. 2017;173:2323-2334. Epub 2017 Jul 27
Siegfried A, Cances C, Denuelle M, Loukh N, Tauber M, Cavé H, Delisle MB. Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature. Am J Med Genet A. 2017;173:1061-1065.
Bertola DR, Pereira AC, Albano MJ, De Oliveira PS, Kim CA, Krieger JE. PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype. Genet Test. 2006;10:186-191.
Reynolds G, Gazzin A, Carli D, Massuras S, Cardaropoli S, Luca M, Defilippi B, Tartaglia M, Ferrero GB, Mussa A. Update on the clinical and molecular characterization of noonan syndrome and other RASopathies: a retrospective study and systematic review. Int J Mol Sci. 2025;26:3515.
Chinton J, Huckstadt V, Gravina P, Obregon G. Caracterización clínica y molecular de niños con síndrome de Noonan y otras RASopatías en Argentina. [Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina]. Arch Argent Pediatr. 2019;117:330-337. [Spanish]
Jorge AAL, Malaquias AC, Arnhold IJP, Mendonca BB. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway. Horm Res. 2009;71:185-193. Epub 2009 Mar 4
Motta M, Fasano G, Gredy S, Brinkmann J, Bonnard AA, Simsek-Kiper PO, Gulec EY, Essaddam L, Utine GE, Guarnetti Prandi I, Venditti M, Pantaleoni F, Radio FC, Ciolfi A, Petrini S, Consoli F, Vignal C, Hepbasli D, Ullrich M, de Boer E, Vissers LELM, Gritli S, Rossi C, De Luca A, Ben Becher S, Gelb BD, Dallapiccola B, Lauri A, Chillemi G, Schuh K, Cavé H, Zenker M, Tartaglia M. SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype. Am J Hum Genet. 2021;108:2112-2129. Epub 2021 Oct 8
Markholt S, Andreasen L, Bjerre J, Gregersen PA, Andersen BN. Autosomal recessive Noonan-like syndrome caused by homozygosity for a previously unreported variant in SPRED2. Eur J Med Genet. 2023;66:104695. Epub 2023 Jan 3
Van Der Burgt I. Noonan syndrome. Orphanet J Rare Dis. 2007;2:4.
Carcavilla A, Suárez-Ortega L, Rodríguez Sánchez A, Gonzalez-Casado I, Ramón-Krauel M, Labarta JI, Quinteiro Gonzalez S, Riaño Galán I, Ezquieta Zubicaray B, López-Siguero JP. Síndrome de Noonan: actualización genética, clínica y de opciones terapéuticas [Noonan syndrome: genetic and clinical update and treatment options]. An Pediatr (Engl Ed). 2020;93:61.e1-61.e14. [Spanish]
El Bouchikhi I, Belhassan K, Moufid FZ, Iraqui Houssaini M, Bouguenouch L, Samri I, Atmani S, Ouldim K. Noonan syndrome-causing genes: Molecular update and an assessment of the mutation rate. Int J Pediatr Adolesc Med. 2016;3:133-142. Epub 2016 Aug 18
Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab. 2011;25:161-179.
Lores J, Prada CE, Ramírez-Montaño D, Nastasi-Catanese JA, Pachajoa H. Clinical and molecular analysis of 26 individuals with Noonan syndrome in a reference institution in Colombia. Am J Med Genet C Semin Med Genet. 2020;184:1042-1051. Epub 2020 Dec 10
Kızılcan Çetin S, Ramoğlu MG, Şıklar Z, Özsu E, Aycan Z, Tutar HE, Berberoğlu M. The effect of growth hormone therapy on cardiac outcomes in Noonan syndrome: long term follow-up results. J Clin Res Pediatr Endocrinol. 2022;14:422-432. Epub 2022 Jul 21
Turner AM. Noonan syndrome. J Paediatr Child Health. 2014;50:E14-20. Epub 2011 Jul 19.
Zenker M, Edouard T, Blair JC, Cappa M. Noonan syndrome: improving recognition and diagnosis. Arch Dis Child. 2022;107:1073-1078. Epub 2022 Mar 4
Malaquias AC, Jorge AAL. Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity. Mol Cell Endocrinol. 2021;519:111040. Epub 2020 Oct 1
Dahlgren J, Noordam C. Growth, endocrine features, and growth hormone treatment in Noonan syndrome. J Clin Med. 2022;11:2034
Romano AA. Growth and Growth hormone treatment in Noonan syndrome. Pediatr Endocrinol Rev. 2019;16:459-464.
Fowlkes JL, Thrailkill KM, Bunn RC. RASopathies: the musculoskeletal consequences and their etiology and pathogenesis. Bone. 2021;152:116060. Epub 2021 Jun 16
Ziegler A, Loundon N, Jonard L, Cavé H, Baujat G, Gherbi S, Couloigner V, Marlin S. Noonan syndrome: an underestimated cause of severe to profound sensorineural hearing impairment. Which clues to suspect the diagnosis? Otol Neurotol. 2017;38:1081-1084.
Dahlgren J. GH therapy in Noonan syndrome: review of final height data. Horm Res. 2009;72(Suppl 2):46-48. Epub 2009 Dec 22
Jorge AAL, Edouard T, Maghnie M, Pietropoli A, Kelepouris N, Romano A, Zenker M, Horikawa R. Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status. Endocr Connect. 2022;11:e210615.
Mcwilliams GD, Santacruz K, Hart B, Clericuzio C. Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy. Am J Med Genet A. 2016;170:195-201. Epub 2015 Sep 17
Smpokou P, Zand DJ, Rosenbaum KN, Summar ML. Malignancy in Noonan syndrome and related disorders. Clin Genet. 2015;88:516-522. Epub 2015 Mar 4
Sodero G, Cipolla C, Pane LC, Sessa L, Malavolta E, Arzilli F, Leoni C, Zampino G, Rigante D. Efficacy and safety of growth hormone therapy in children with Noonan syndrome. Growth Hormone and IGF Research. Churchill Livingstone; 2023; vols. 69-70, p. 1-19.
Tamburrino F, Scarano E, Schiavariello C, Perri A, Pession A, Mazzanti L. Endocrinological manifestations in RASopathies. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics. John Wiley and Sons Inc; 2022. vol. 190, p. 471-477.
Giacomozzi C, Deodati A, Shaikh MG, Ahmed SF, Cianfarani S. The impact of growth hormone therapy on adult height in Noonan syndrome: a systematic review. Horm Res Paediatr. 2015;83:167-176.
Ney G, Gross A, Livinski A, Kratz CP, Stewart DR. Cancer incidence and surveillance strategies in individuals with RASopathies. Am J Med Genet C Semin Med Genet. 2022;190:530-540. Epub 2022 Dec 19
Noonan JA, Kappelgaard AM. The efficacy and safety of growth hormone therapy in children with Noonan syndrome: a review of the evidence. Horm Res Paediatr. 2015;83:157-166. Epub 2014 Dec 10
